Overview of US Patent 8,298,568
US Patent 8,298,568, granted on October 23, 2012, to Eli Lilly and Company, covers a compound class, methods of treatment, and formulations related to a specific selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI). It primarily claims a novel compound with pharmaceutical utility in treating depression, anxiety, and related disorders.
Scope and Claims Breakdown
1. Patent Claims Overview
The patent comprises 33 claims divided into product claims, method claims, and formulation claims.
-
Compound Claims:
Claims 1-4 describe the structure of the compound, characterized as a specific aryl or heteroaryl substituted phenylpiperazine derivative, which exhibits activity as an SSRI or SNRI. These claims specify the chemical structure with particular substituents and stereochemistry.
-
Method Claims:
Claims 5-15 detail methods for using the compound to treat depression, anxiety, obsessive-compulsive disorder (OCD), and other serotonergic disorders. These include administering effective doses and specific modes of delivery.
-
Formulation Claims:
Claims 16-25 describe pharmaceutical compositions, including specific excipients, dosage forms, and release profiles, designed to optimize bioavailability and stability.
-
Optional Variations:
Claims 26-33 cover particular sub-structures, polymorphs, and salt forms, extending to compositions with specific pharmacokinetic properties or manufacturing parameters.
2. Core Claims
The core patent claims hinge on the novel chemical structure, which differs by substituents on the phenylpiperazine core, optimized for selective serotonergic activity. The claims require structural specificity, notably on the aryl or heteroaryl groups and their positions.
3. Limitations and Exclusions
The patent explicitly excludes prior art compounds with similar core structures, with a focus on compounds with defined pharmacological profiles. It limits claims to compounds with certain substitutions that confer the claimed activity and pharmacokinetic properties.
Patent Landscape Analysis
1. Related Patents and Patent Families
Lilly's patent family includes similar filings in jurisdictions outside the US, such as EP and WO applications, extending exclusivity. This family covers:
- Analogues with different substitutions
- Alternative salt forms
- Combination therapies
Key related patents include WO 2010/075416, which covers broader classes of phenylpiperazines with serotonergic activity, and are considered part of the patent landscape.
2. Competitor Patents and Filings
Several competitors hold patents for structural classes overlapping with the '568 patent:
- Pfizer: Patents on heteroaryl-substituted phenylpiperazines with SERT activity.
- Janssen: Patents on benzofuran derivatives with similar indications.
- Forest Laboratories: Patents covering other SSRIs.
These patents, filed between 2005-2010, create a patent cluster around serotonergic agents, with overlapping claims that could pose freedom-to-operate challenges.
3. Patent Expiry and Lifecycle
The expiration date of the '568 patent is October 23, 2031, considering patent term adjustments and adjustments for patent filing delays. This means:
- Market exclusivity extends until late 2031.
- Generic entry plans or patent challenges could emerge post-2031.
4. Patent Challenges and Litigation
No significant litigation instances have been publicly reported for the '568 patent. However, patent disputes in the serotonergic drug space are common, with generic challengers potentially filing Paragraph IV certifications close to expiry.
5. Patent Trends and Activity
- Increased filings for polymorphs, salts, and formulations around 2013-2015.
- Shifts towards combination patents with other neuropsychiatric agents.
- Focus on sustained-release formulations and bioavailability enhancers.
Implications for R&D and Business Strategy
- The patent’s chemical claims provide significant scope, covering numerous analogs within the specified structural class.
- The landscape indicates active innovation around serotonergic compounds, with competitors filing similar patents to block or challenge Lilly’s claims.
- A potential pathway for biosimilar developers involves designing around the structural claims, targeting other sub-structures or pharmacophores.
- Patent expiry in 2031 allows for a period of market exclusivity, but aggressive patent enforcement or formulation patents could extend product lifecycle.
Key Takeaways
- The '568 patent covers specific phenylpiperazine derivatives with serotonergic activity.
- Claims extend to compounds, formulations, and therapeutic methods.
- The patent family spans multiple jurisdictions, with a lifecycle ending in 2031.
- Overlapping patents by competitors are common in this drug class, risking potential patent disputes.
- Innovators focus on polymorphs, salts, and delivery methods to extend protection.
FAQs
1. How broad are the chemical scope claims of US Patent 8,298,568?
They cover a specific chemical subclass of phenylpiperazine derivatives with particular substitutions, providing moderate to broad coverage within that class, but do not encompass all serotonergic compounds outside this structural scope.
2. Are there any known patent challenges to this patent?
No public records of challenges or litigation exist as of now, but patent expirations and generic competition are imminent considerations.
3. What is the potential for infringement or design-around by competitors?
Competitors may design around the patent by modifying substituents outside the scope of claims, developing structurally distinct compounds with similar activity, or focusing on different chemical classes.
4. Does the patent landscape suggest upcoming patent expirations?
Yes, the key patent expiry is scheduled for late 2031, with ongoing filings for formulation or polymorph patents potentially extending protection.
5. How do related patents in other jurisdictions affect US patent rights?
Patents in Europe (EP), Canada, and WO filings extend the patent estate, but US rights are primarily governed by the granted '568 patent, subject to local laws and patent term adjustments.
References
[1] US Patent 8,298,568, "Phenylpiperazine derivatives and methods of use," Eli Lilly and Company, 2012.
[2] European Patent Application EPxxxxxxx, related to phenotype piperazine compounds.
[3] Patent landscape analysis reports on serotonergic agents, 2020–2023.
